Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. - sprookjes - yvandenbroek - TriplyDB

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

http://www.wikidata.org/entity/Q34910366

about

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Review of vancomycin-induced renal toxicity: an update Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics Strategies for appropriate antibiotic use in intensive care unit Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Optimizing the Clinical Use of Vancomycin Vancomycin activates σ(B) in vancomycin-resistant Staphylococcus aureus resulting in the enhancement of cytotoxicity Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis Guidelines for therapeutic drug monitoring of vancomycin: a systematic review The impact of a pilot continuing professional development module on hospital pharmacists' preparedness to provide contemporary advice on the clinical use of vancomycin 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.Dosing of antibacterial agents in obese adults: does one size fit all?The study of vancomycin use and its adverse reactions associated to patients of a Brazilian university hospital.A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin.Prognosis of patients with methicillin-resistant Staphylococcus aureus bloodstream infection treated with teicoplanin: a retrospective cohort study investigating effect of teicoplanin minimum inhibitory concentrations.Vancomycin-Induced Thrombocytopenia: A Narrative Review.Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China.Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience.Staphylococcus aureus - antimicrobial resistance and the immunocompromised child.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Clinical pearls in infectious diseases.Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci.Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.Pharmacokinetics of Antimicrobials in Obese Children.Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections The Whole Price of Vancomycin: Toxicities, Troughs, and Time Vancomycin monitoring in children using bayesian estimation.Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.The standard one gram dose of vancomycin is not adequate prophylaxis for MRSA

P2860

Q24606291-4608154D-50FE-4ECE-A7BD-A24AB3335D35 Q26746932-74EE67AF-7CA9-41B9-BD4A-01F42F63911F Q26770913-01C899D7-540A-405C-8F9B-2F117CF4BDD8 Q26853629-58034E87-0358-40A4-9A75-A67FB4B37EB6 Q27002517-ED49061C-E1AA-4D11-9666-CAE4DD513105 Q27009221-E100D56B-AECB-4CE4-9118-FA47FFFA6514 Q28069334-ED5FD946-5F26-4867-B29B-D33FB56C913E Q28476797-0C6692FE-72BC-4351-90EF-871B20CEEEC5 Q28481497-4760D783-3910-4ED5-9E60-8AAE4CA4C49D Q28534516-748A5A7A-25CF-4C56-80BD-174FF6AAD596 Q28539717-A7F84376-A18D-440E-B961-366006887FED Q30152109-CD4ACE99-16E2-494B-86E9-ECAEB01F3A4B Q30274757-074E446B-2C8A-4F2E-9408-EF31D5D5342F Q30362353-4FBA9CDC-9BC6-4DC0-9B9A-E772F6BEB29D Q33396270-9E4C8858-4C48-4E05-B3A1-6D8C210F9D98 Q33398776-53F9035E-422E-4E91-8412-A98F0B009F38 Q33407156-7051F363-5F13-4233-B1B3-2C6A4A2AFB91 Q33436796-8E690B82-7DB3-4FC0-8D7F-4B08720D1326 Q33585827-99941D53-962E-40FF-B3E4-066792FF4550 Q33602468-321EF6B6-A83B-4483-9A41-841D97AF0B09 Q33604961-8E39FA7B-D5B4-43BA-AB5F-AF67E1377951 Q33617737-2753BED3-3AD0-4311-B580-D3D95643D43E Q33620412-B107013C-1FE9-4AA1-933B-92D2EDC0C036 Q33642100-9F92D91F-2DD7-409E-9C58-7B6E9664BB46 Q33703519-0A8E59CE-0ED4-4CAA-8BC5-AB4A81D2836A Q33704733-F9CE730A-9E77-4058-8167-32C12A0032CE Q33732555-F9A2A56E-385D-4BE5-98B6-39FB2480147F Q33797925-0C23D880-34C4-4A60-8091-37B11222F7F3 Q33798143-1F100017-22AE-4170-B5EB-F3347F815000 Q33806504-DFF14C13-2617-4297-A42E-F83A10AC5006 Q33821959-FCDF8244-66CB-41F9-8529-03E55314EEA2 Q33844670-17187A5B-BF2A-4D8E-909E-71FCD3DD64E3 Q33855312-988ABDEA-CF36-4AC5-941B-40383300502C Q33881584-FBDF0487-4487-4858-A60B-DAC589567C4C Q33885191-74BAAC24-0687-41E4-A49D-8DC2AF64E9EF Q33911485-360058FE-6FC2-4068-B38C-99E605224738 Q33939018-FC44F11D-F984-45E2-9B92-CB9000877484 Q33949459-57FEE053-D37A-47EF-937D-5A14F342BDA8 Q33997671-EBCBEAD3-567A-4598-920C-3B7B6EED3F75 Q34024012-2C9EF31E-0188-49AA-8AAF-73391C2F130A

P2860

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

http://www.wikidata.org/entity/Q34910366

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@ast

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@en

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@nl

type

label

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@ast

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@en

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@nl

prefLabel

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@ast

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@en

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@nl

P1433

Q34910366-F3E1576C-4A6E-433F-92E1-9ACEAFA65BE2

P1476

Q34910366-EABE54D8-C41F-4038-9AC7-6A5A5176A54C

P2093

Q34910366-3D734C1A-87E9-4EDF-8009-4EDA17BE368B

Q34910366-40652753-A983-475D-944F-4079EC4C9F89

Q34910366-43721D21-FCBE-41E2-8B0C-056644B0F43E

Q34910366-73F73502-9620-4B5D-9904-4AFC3F6FD11E

Q34910366-8B8BBACD-AAA0-4A1B-BB88-61D16D21A398

Q34910366-8D7FC4C1-20E4-42FE-BD1A-ABEA57448752

Q34910366-EA7DDA45-9A8C-4E1E-89F3-2699CE106F2C

Q34910366-F9B8E33B-DDC7-4CFA-BEB3-256302CD02F0

P304

Q34910366-C6E3185E-C3B8-4B93-97F8-519BBECB23C8

P31

Q34910366-99FBC144-60F9-420A-99FF-0A4AD9A9408A

P356

Q34910366-E4AA8D16-D7BE-41AE-B922-DE5DC0F35693

P433

Q34910366-69D9656E-F58D-46E2-BE51-0E2062FD581A

P478

Q34910366-CCE96A99-EA0D-4CFE-A347-D0B90996B04C

P577

Q34910366-0F543CD2-B646-4FB8-AF08-63C7429178F6

P5875

Q34910366-4B3AFDAE-A592-441A-9999-FCCE9EFC9BB6

P698

Q34910366-ACEBEAED-55BE-4A8E-ACCE-EB54A00A7365

P921

Q34910366-AD05D85C-5A05-409D-B993-7BABF4D2C955

P356

P1433

American Journal of Health-System Pharmacy

P1476

Therapeutic monitoring of vanc ...... fectious Diseases Pharmacists.

@en

P2093

Ben Lomaestro

http://www.w3.org/2001/XMLSchema#string

Donald P Levine

http://www.w3.org/2001/XMLSchema#string

John C Rotschafer

http://www.w3.org/2001/XMLSchema#string

Joseph R Dalovisio

http://www.w3.org/2001/XMLSchema#string

Marianne Billeter

http://www.w3.org/2001/XMLSchema#string

Michael Rybak

http://www.w3.org/2001/XMLSchema#string

Robert Moellering

http://www.w3.org/2001/XMLSchema#string

William Craig

http://www.w3.org/2001/XMLSchema#string

P304

82-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2146/AJHP080434

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23688024

http://www.w3.org/2001/XMLSchema#string

P698

19106348

http://www.w3.org/2001/XMLSchema#string

P921